The race to develop muscle-preserving treatments alongside popular obesity drugs like Eli Lillys (NYSE:LLY) Zepbound and Novo ...

At a time when Novo Nordisk has appeared to be slipping behind rival Eli Lilly and its blockbuster Zepbound (tirzepatide) in ...

Participants in trial of amycretin injectable obesity drug lost an average of 24% of their body weight on highest dose ...

The shipments have vaulted Ireland, a country of only five million people, into the second-largest goods-trade imbalance with the U.S., trailing only China.

Novo Nordisk A/S’s latest experimental obesity drug helped patients lose as much as 24.3% of their weight in a small study, ...

Investing.com -- The American College of Cardiology released new recommendations on Friday stating that millions more ...

The U.S. trade deficit with Ireland has surged as $36 billion in hormone shipments for weight-loss and diabetes drugs were flown in to meet demand and avoid tariffs.

Treatments designed to help patients preserve muscle while losing weight with popular obesity drugs by Eli Lilly and Novo ...

GLP-1 drugs such as Wegovy and Zepbound are growing increasingly prominent. But some food ingredients can also cause the body ...

Millions more Americans should be taking weight-loss drugs to prevent heart disease, according to the American College of ...

A radical shifting of trade flows has given Ireland the second-biggest trade imbalance with the U.S. after China, mostly due to demand for weight-loss drugs.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.